Hydroxylamine substituted imidazo-containing compounds

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/437 (2006.01) A61K 31/4375 (2006.01) A61K 31/4745 (2006.01) A61P 31/12 (2006.01) A61P 37/02 (2006.01) C07D 471/04 (2006.01) C07D 471/14 (2006.01)

Patent

CA 2535120

Imidazo-containing compounds (e.g., imidazoquinolines, imidazonaphthyridines, imidazopyridines) with a hydroxylamine substituent at the 1-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

L'invention concerne des composés contenant une structure imidazo (imidazoquinolines, imidazonaphthyridines et imidazopyridines, par exemple) avec un substituant hydroxylamine en position 1, des compositions pharmaceutiques contenant ces composés, des produits intermédiaires et des méthodes d'utilisation de ces composés comme immunomodulateurs, pour induire la biosynthèse de cytokines chez des animaux et pour traiter des maladies, y compris des maladies virales et cancéreuses.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Hydroxylamine substituted imidazo-containing compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hydroxylamine substituted imidazo-containing compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxylamine substituted imidazo-containing compounds will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1590657

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.